NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Collaborates with Major Universities for the Evaluation of SofPulse(R) for Orthopedic Surgeries

February 10, 2020 09:45:29

Endonovo Therapeutics (OTCQB: ENDV) today announced the evaluation of its SofPulse(R) device at major universities for orthopedic surgeries. Endonovo’s FDA-Cleared SofPulse(R) is a non-invasive device utilized for the reduction of postoperative pain and edema and represents a low-cost drug-free solution for reducing opioid usage, accelerating patient recovery and preventing opioid addiction following surgical procedures. “We are pleased to announce SofPulse(R) is now being evaluated at major medical universities. We believe this is a unique opportunity for SofPulse(R) to be evaluated, and upon completion and approval, be used as a standard of healthcare moving forward,” Endonovo Therapeutics CEO Alan Collier said in the news release. “We are also optimistic SofPulse(R) can be used by professors as a standard medical device which can be implemented in the educational process for all medical professionals. Although we are in the early stages, the university administrators and professors are expediting the evaluation process.”

To view the full press release, visit http://nnw.fm/ViL41

About Endonovo Therapeutics

Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals(R) therapeutic devices. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders, including traumatic brain injury (“TBI”), acute concussions, post-concussion syndrome and multiple sclerosis. The Company’s noninvasive Electroceutical(R) therapeutic device, SofPulse(R), which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company’s current portfolio of preclinical-stage Electroceuticals(R) therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The Company’s noninvasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. For more information, visit www.Endonovo.com.

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

NetworkNewsWire is part of the InvestorBrandNetwork.